INCY
Incyte Corporation · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -2.2% · net new positions -4.2% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 433.49K | $48.73M | n/a | −2 |
| Q2 2026 | 154 | 0 | 131.73M | $14.93B | +4 | −5 |
| Q1 2026 | 158 | +1 | 132.61M | $12.47B | +5 | −5 |
| Q4 2025 | 156 | -1 | 139.13M | $13.74B | +1 | −1 |
| Q3 2025 | 24 | 0 | 89.63M | $7.60B | n/a | −1 |
| Q2 2025 | 22 | +1 | 88.20M | $6.01B | +1 | n/a |
| Q1 2025 | 18 | -1 | 44.33M | $2.68B | n/a | −1 |
| Q4 2024 | 19 | +1 | 43.85M | $3.03B | +1 | n/a |
| Q3 2024 | 17 | 0 | 35.50M | $2.35B | +1 | −1 |
| Q2 2024 | 17 | n/a | 33.47M | $2.03B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 19.95M | -0.9% | $1.69B | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 2 | BlackRock ✦ (passive) | 17.89M | -0.3% | $1.52B | 0.0% | ▼ Trim | 2 | SEC ↗ ×21 |
| 3 | Dodge & Cox ✦ | 13.93M | -4.5% | $1.18B | 0.6% | ▼ Trim | 6 | SEC ↗ |
| 4 | State Street Global Advisors ✦ (passive) | 9.68M | -2.0% | $820.69M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 5 | AQR Capital Management ✦ | 7.92M | -3.4% | $667.56M | 0.4% | ▼ Trim | 6 | SEC ↗ ×8 |
| 6 | Renaissance Technologies ✦ | 4.53M | +16.6% | $384.03M | 0.5% | ▲ Add | 6 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passive) | 4.49M | +3.2% | $378.99M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 8 | Arrowstreet Capital ✦ | 3.10M | +13.7% | $263.25M | 0.2% | ▲ Add | 4 | SEC ↗ |
| 9 | Morgan Stanley ✦ | 2.64M | n/a | $223.96M | 0.0% | n/c | 1 | SEC ↗ ×13 |
| 10 | Goldman Sachs Group ✦ | 1.29M | n/a | $109.81M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 11 | Fidelity (FMR) ✦ | 1.27M | +10.0% | $107.88M | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 12 | JPMorgan Chase ✦ | 895.44K | n/a | $75.95M | 0.0% | n/c | 1 | SEC ↗ ×28 |
| 13 | T. Rowe Price ✦ | 781.35K | +238.6% | $66.27M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 14 | Point72 Asset Management ✦ | 477.07K | -51.6% | $40.46M | 0.1% | ▼ Trim | 5 | SEC ↗ |
| 15 | Gotham Asset Management ✦ | 234.43K | +24.8% | $19.88M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 16 | ARK Investment Management ✦ | 147.34K | -4.1% | $12.50M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 17 | Bridgewater Associates ✦ | 131.28K | -66.7% | $11.13M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 18 | D. E. Shaw & Co. ✦ | 63.77K | -84.3% | $5.41M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 19 | Two Sigma Investments ✦ | 48.15K | -25.2% | $4.08M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 20 | Millennium Management ✦ | 40.62K | -74.3% | $3.44M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 21 | Fisher Asset Management ✦ | 39.95K | +33.5% | $3.39M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 22 | Citadel Advisors ✦ | 33.84K | +847.7% | $2.87M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 23 | Wellington Management ✦ | 21.08K | -72.2% | $1.79M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 24 | Marshall Wace ✦ | 16.04K | -98.7% | $1.36M | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Norges Bank | $96.78M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 805 holders, 201.47M shares, $18.13B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 2.64K sh · $297,780
Officer · 13.98K sh · $1.69M
Officer · 9.23K sh · $1.11M
Officer · 10.80K sh · $1.36M
Officer · 10.80K sh · $1.30M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology